Hola,
¿eres nuevo aquí?

Registrate y conecta tu empresa con financiación pública, partners y proyectos.

LungCARD

Financiado

Blood test for clinical therapy guidance of non small cell lung cancer patients

Lung cancer is the most common cancer worldwide. NSCLC alone make up about 75% of all lung cancers and most hospitals currently test all NSCLC patients for EGFR mutations (pharmacogenomics) for treatment decision (personalised med... ver más

31/10/2022

STAB VIDA INVESTIG...

1M€

Presupuesto del proyecto: 1M€

Líder del proyecto

STAB VIDA INVESTIGACAO E SERVICOS EM CIENCIAS... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Ver 20 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2022-10-31

Línea de financiación objetivo El proyecto se financió a través de la siguiente ayuda:

MSCA-RISE-2016: Research and Innovation Staff Exchange

I+D

Cerrada hace 8 años

0% 94% 100%

20 Participantes

STAB VIDA INVESTIGACAO E SER...

603.00K€ | Lider

PARSEQ LAB

N.D. | Participante

UTS

49.50K€ | Participante

Institut Pasteur Du Maroc

Últimas noticias

29-11-2024: IDAE En las últimas 48 horas el Organismo IDAE ha otorgado 4 concesiones

29-11-2024: ECE En las últimas 48 horas el Organismo ECE ha otorgado 2 concesiones

29-11-2024: CMVAMADRID En las últimas 48 horas el Organismo CMVAMADRID ha otorgado 37 concesiones

Duración del proyecto: 70 meses Fecha Inicio: 2016-12-02
Fecha Fin: 2022-10-31

Presupuesto del proyecto 1M€

Descripción del proyecto Lung cancer is the most common cancer worldwide. NSCLC alone make up about 75% of all lung cancers and most hospitals currently test all NSCLC patients for EGFR mutations (pharmacogenomics) for treatment decision (personalised medicine) – i.e., patients with mutation(s) in EGFR gene should receive a EGFR-Tyrosine Kinase Inhibitor (TKI) drug (e.g. afitinib) treatment; while those that do not present mutations in such gene, should be treated with chemotherapy. Currently, the laboratories use PCR and Sanger sequencing technologies to perform the EGFR analysis from tumour biopsies - Fixed Paraffin Embedded (FFPE) samples. Still, some patients (e.g., 30% in UK) may never get histological confirmation because they are too sick to make a biopsy. Furthermore, the results obtained with current methods still present low quality, mainly due to poor quality/low yield of DNA extracted from FFPE samples. The FP7 LungCARD project (www.lungcard.eu) has developed and demonstrated a LungCARD system - an automatic system composed by microfluidic chip and chip analyser - that allows to capture circulating tumour cells (CTCs) from blood samples, amplify by multiplex PCR and detect EGFR mutations, including also a software for data analysis and report. Although this new blood test has proven to be faster, cost-effective and human error-free, the detection of somatic mutations in EGFR gene at frequencies lower than 20% is still a weak point. Therefore, the main project’s goal is to benefit from this technology, through the development, improvement, integration and validation of the LungCARD system with NGS workflow and development of a software for automatic reporting clinical results. However, LungCARD project aims to go further, by putting together a global and unique network of multidisciplinary scientists for exchange of knowledge and research training focused on non-small cell lung cancer.

Conecta tu I+D

Entra hoy

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores